BioSpace News Archive

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a leading developer of advanced cold chain management tools for cell and gene therapies, and soon to be acquired by BioLife

Genome Canada, Ontario Institute for Cancer Research and Thermo Fisher Scientific to focus on pancreatic, prostate and breast cancer

Verification Testing at the Japanese Experiment Module “Kibo” to Start in 2019

The rise in breast cancer cases across the world, especially in the Americas and Europe, have increased the need to conduct breast cancer screening.

DEEPER OUS is a 100-patient prospective, non-randomized, multicenter trial designed to assess the safety and efficacy of the Temporary Spur Stent System compared to a meta-analysis of published data for percutaneous transluminal angioplasty (PTA) in treating patients with infrapopliteal disease.

Positive Preliminary Results Demonstrate Statistical Superiority to Sham with the World’s Smallest Battery-Free Spinal Cord Stimulator

The Company currently estimates it will spend $10.0 million on the build out and expects to break ground in 2020 with the new facility opening in 2022.

First Quarter Amended Results Include Upward Revisions to Net Sales and Gross Profit, and a Reduction of Operating Loss

Investor and philanthropist to discuss entrepreneurship and his commitment to leveraging technology to expand access to opportunities for all members of society

Alfa Plus is a 100-percent natural therapy, has a two-year warranty and is currently available for purchase on Amazon and the Solio website.